| Literature DB >> 34063572 |
Arrin Brooks1, Alastair T Hoyt2.
Abstract
With more than two decades of experience and thousands of patients treated worldwide, deep brain stimulation (DBS) has established itself as an efficacious and common surgical treatment for movement disorders. However, a substantial majority of patients in the United States still undergo multiple, "staged" surgeries to implant a DBS system. Despite several reports suggesting no significant difference in complications or efficacy between staged and non-staged approaches, the continued use of staging implies surgeons harbor continued reservations about placing all portions of a system during the index procedure. In an effort to eliminate multiple surgeries and simplify patient care, DBS implantations at our institution have been routinely performed in a single surgery over the past four years. Patients who underwent placement of new DBS systems at our institution from January 2016 to June 2019 were identified and their records were reviewed. Revision surgeries were excluded. Total operative time, length of stay and rates of surgical site infections, lead fracture or migration, and other complications were evaluated. This series expands the body of evidence suggesting placement of a complete DBS system during a single procedure appears to be an efficacious and well-tolerated option.Entities:
Keywords: deep brain stimulation; interoperative neurophysiology; movement disorders; stereotactic surgery; surgical technique
Year: 2021 PMID: 34063572 PMCID: PMC8147611 DOI: 10.3390/brainsci11050592
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Figure 1Unilateral versus bilateral placement in included patients.
Figure 2Conditions treated and brain targets in included patients.
Complications suffered by patients within 90 days of surgery and at 90 days or longer after surgery.
| Within 90 Days | >90 Days | Total (as of the Last Follow-Up) | ||||
|---|---|---|---|---|---|---|
| Number | Percent | Number | Percent | Number | Percent | |
| Infection | 2 | 2.7% | 2 | 2.7% | 4 | 5.5% |
| Lead | 1 | 1.4% | 1 | 1.4% | 2 | 2.7% |
| Wound | 0 | 0% | 2 | 2.7% | 2 | 2.7% |
| Hypotension | 1 | 1.4% | 0 | 0% | 1 | 1.4% |
| IPG Site | 1 | 1.4% | 0 | 0% | 1 | 1.4% |
| Total | 6 | 8.2% | 5 | 6.8% | 11 | 15.1% |
Readmissions within 90 days of surgery.
| Number | Percent | |
|---|---|---|
| Infection | 2 | 2.7% |
| Lead Fracture | 1 | 1.4% |
| Hypotension | 1 | 1.4% |
| IPG Site Hematoma | 1 | 1.4% |
| Pain | 1 | 1.4% |
| Total | 6 | 8.2% |
Figure 3Flow chart of outcomes.
Complications in other published works.
| No. of Patients (Electrodes) | Staging | Infection | Hardware Complication | Wound Dehiscence/Erosion | Hemorrhage | Seizures | Loss of Efficacy | Other | |
|---|---|---|---|---|---|---|---|---|---|
| Abode-Iyamah, et al. (2019) | 242 (464) | S: 228 | S 15 (6.6%) | NR | S: 9 (4.0%) | NR | NR | NR | Postoperative Seroma |
| Chen, et al. (2017) | 284 (490) | S: 200 | S: 3 (1.5%) | High impedance | S: 1 (0.3) | S: 3 (1.5%) | S: 2 (1%) | NR | |
| Fenoy (2014) | 728 (1333) | Transitioned from N to S, data not segregated | 23 (3.2%) | Lead malposition 9 (1.2%) | 4 (0.5%) | Symptomatic 8 (1.1%) | 5 (0.7%) | 29 (4%) | IPG flipped, malpositioned or discomfort 8 (1.1%) |
| Petraglia (2016) | 713 (1426) | Sim Bilat: 556 | Sim Bilat: 24 (4.3%) | Sim Bilat: 3 (0.5%) | NR | Sim Bilat: 16 (2.9%) | NR | NR | Lead Revision |
| Doshi (2010) | 153 (298) | All staged | 6 (3.9%) | Lead malposition 4 (2.6%) | 1 (0.7%) | 2 (1.3%) | NR | 2 (1.3%) | |
| Voges, et al. (2006) | 262 (472) | S: 194 (74.1%) | 15 (5.7%) | Electrode damage/fracture 4 (2.2%) | 1 (0.6%) | 1 (0.4%) | 0 (0%) | NR | IPG implantation site hematoma 3 (1.25) |
| Seijo, et al. (2011) | 130 (252) | All staged | 2 (1.5%) | Lead fracture 1 (0.8%) | NR | 9 (6.9%) | 13 (10%) | NR | CSF leak 1 (0.8%) |
| Tolleson, et al. (2014) | 447 (823) | All staged | 26 (5.8%) | Lead migration 2 (0.5%) | Infected group 8 (1.8%) | 2 (0.5%) | 1 (0.2%) | NR | Pain along apparatus 4 (0.9%) |
| Kochanski, et al. (2019) | 178 (270) | Both Staged and Nonstaged procedures include; not segregated | 3 (1.7%) | Malpositioned lead 0 (0%) | NR | 3 (1.7%) | 2 (1.1%) | NR | |
| Falowski, et al. (2015) | 432 (606) | S: 326 (475) | S: 11 (3.4%) | Lead fractures | S: 3 (0.9%) | S: 12 (3.7%) | NR | S: 17 (5.2%) | Extension lead coiling |
| Morishita, et al. (2017) | 132 (138) | All staged | 17 (12.9%) | Fracture 7 (5.1%) | NR | Symptomatic ICH 5 (3.8%) | 9 (6.8%) | NR | Air embolus 2 (1.5%) |
Total number (% of event by number of patients). S = Staged (IPG implanted in subsequent surgery); N = Nonstaged (DBS system including IPG implanted in one operative session); Sim Bilat = Simultaneous Bilateral (DBS leads implanted in each hemisphere in one surgery); Staged Bilat = Staged Bilateral (each hemisphere implanted in staged surgeries); NR = Not Reported; ICH = intracranial hemorrhage; IVH = intraventricular hemorrhage.